TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00821431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Device
Description: Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
Study: NCT02821468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droglican
Description: Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol or oral NSAIDs excluding COX2 inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol or oral NSAIDs excluding COX2 inhibitors
Study: NCT03605563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling
Description: Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (\>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (\<10 Hz) with an intensity that produces motor contraction.
Study: NCT03552822

Intervention type: OTHER
Intervention: ERAS Protocol Implementation
Description: Implementation of ERAS Protocol Implementation
Study: NCT02646748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: Itacitinib tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB050465
Description: INCB050465 tablets administered orally once daily.
Study: NCT03537599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Description: Given via infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01283698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: LAS 41004 dosage 1
Description: dosage 1, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: LAS 41004 dosage 2
Description: LAS 41004 dosage 2, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: LAS 41004 dosage 3
Description: dosage 3, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: placebo
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Active Comparator,once daily
Study: NCT02263534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single incision minisling
Description: midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tension free vaginal tape
Description: midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
Study: NCT01431534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Description: Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m\^2, 28 mg/m\^2, or 33 mg/m\^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
Study: NCT01382264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Assisted Decision Support
Description: Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
Study: NCT01704833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)
Description: The PFCBT is a 15-week Program that includes weekly group and individual sessions.
Study: NCT02463188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Fitness Intervention
Description: The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
Study: NCT00194844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Caring
Description: Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Caring
Description: Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Caring
Description: Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
Study: NCT04567550

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 1
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 2
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314 Dose 3
Description: AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Steroid
Description: Topical Steroid
Study: NCT01647529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Treatment with topical ganciclovir ointment
Study: NCT01523639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/Placebo
Description: The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin/Placebo
Description: The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks
Study: NCT01585220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA filler
Description: The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA filler
Description: The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
Study: NCT01464229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Iloperidone 1-8 mg for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02896504

Intervention type: DRUG
Intervention: Exposure: Adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Exposure: Adjuvant hormonal therapy treatment
Study: NCT00622882

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infectious disease specialist consultation
Description: Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
Study: NCT02960347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor
Description: Non-invasive focal neuromodulation
Study: NCT02740972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05078216

Intervention type: OTHER
Intervention: Physical exercise intervention
Description: 12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity.
Study: NCT00327054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sativa seed
Study: NCT03211650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic Acid + platelet-rich plasma
Description: Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
Study: NCT04171843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT03211650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: Intra-articular injections of hyaluronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: Intra-articular injections of platelet-rich plasma
Study: NCT01910805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle and Risk Assessment class
Description: Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices.
Study: NCT01605253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
Study: NCT01210989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyllanthus urinaria
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
Study: NCT04622189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action observation training
Description: Integration of four main tools:~* PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~* MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~* EEG data will be collected during video observation using an Enobio wireless system integrated with the platform.
Study: NCT04561752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is the study drug.
Study: NCT02993653

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose Intensity-modulated radiotherapy
Description: Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
Study: NCT01367353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery or debulking surgery
Description: surgery or debulking surgery
Study: NCT04298723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous closure of the LAA (Watchman / Watchman FLX)
Description: LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (WatchmanTM or Watchman FLXTM) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
Study: NCT02679742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxymethylbutyrate
Description: β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
Study: NCT04427553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Peripheral Nerve Stimulation
Description: Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: No intervention
Study: NCT00460551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: 8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: Combination of cisplatin and docetaxel administered as two cycles given every three weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 64 Gy in 32 fractions over 6.5 weeks
Study: NCT01840605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketotifen fumarate
Description: Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
Study: NCT02873273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
Study: NCT02279862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT03228381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOSS Device
Description: The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
Study: NCT03298321

Intervention type: OTHER
Intervention: Effect of Vidaza treatment
Description: The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
Study: NCT02798263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 30 minutes of classical acupuncture using predefined points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stiper
Description: They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
Study: NCT04171843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Allogeneic anti-BCMA CAR T-cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Allogeneic anti-BCMA CAR T-cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Allogeneic anti-BCMA CAR T-cell